The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than androgen deprivation therapy alone. The safety of this treatment combination will also be studied.
Today androgen deprivation therapy has been a standard treatment for metastatic prostate cancer, but as to the special type of prostate cancer-oligometastatic prostate cancer, except for androgen deprivation therapy, whether local treatment can be the part of treatment for it? The purpose of this study is to evaluate whether local treatment combined with androgen deprivation therapy can extend progression-free survival, as well as overall survival and life quality of patients of oligometastatic prostate cancer compared with androgen deprivation therapy alone.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Progression-Free Survival (radiographic progression-free survival)
Time frame: 2 years
Overall survival
Time frame: 3 years
time of PSA progression
Time frame: 3 years
the quality of life
Quality of Life assessed by the EORTC QLQ-C30 questionnaire
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Given subcutaneously or as an injection
Given subcutaneously or as an injection
surgery to remove prostate or radiation therapy to the prostate.